Clinical Trial Update: Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating local ablative therapy for oligometastatic lesions in EGFR-mutated non-small cell lung cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Lung Cancer (NSCLC) | Phase 2 | Status: RECRUITING